Skin Tissue Replacement-Powerpoint presentation

Skin Tissue Replacement-Powerpoint presentation - REPLIDERM...

Info iconThis preview shows pages 1–20. Sign up to view the full content.

View Full Document Right Arrow Icon
REPLIDERM Inc. REPLIDERM Inc. GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
OVERVIEW OVERVIEW z Background/Review of current conditions z Objective of RepliDerm z Production plan z FDA Approval Process z Business/Market Plan
Background image of page 2
BACKGROUND BACKGROUND
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Problem Problem z 270,000 burn victims per year in the U.S. requiring hospitalization z 1.5 million diabetic patients in the U.S. with wound ulcers z Various narcotizing infections (flesh eating infections)
Background image of page 4
Treatments Available Treatments Available z Split thickness autograft z Donor allograft z Synthetic allograft z Synthetic allograft with seeded neo- natal fibroblasts z Temporary covering from biological donor
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Advantages of Existing Advantages of Existing Treatments Treatments $42/in 2 Epidermal autograft required Strong & supple Protective layer 5% Rejection Synthetic (Integra) $102/in 2 Fragile No epidermal graft needed 5% Rejection Synthetic Allograft with Seeded Cells (Epicel) $7/in 2 Disease transmission 10% Rejection Small wounds only Relatively Inexpensive Donor Allograft (AlloDerm) $0 Extensive scarring Limited donor sites Inexpensive No rejection Split Thickness Autograft (Surgical treatment) Price/in 2 Disadvantages Advantages Procedure (Product)
Background image of page 6
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration Template Regeneration Template
Background image of page 7

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration Template Regeneration Template
Background image of page 8
Mechanism for Angiogenesis Mechanism for Angiogenesis
Background image of page 9

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration Template Regeneration Template
Background image of page 10
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration Template Regeneration Template
Background image of page 11

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
On the Market: Integra Dermal Regeneration Template
Background image of page 12
Product Objective Product Objective z To produce a synthetic dermal replacement template that increases the speed of vascularization and quality of burn and wound treatment.
Background image of page 13

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Growth Factors Growth Factors z Basic Fibroblast Growth Factor- BFGF z Acidic Fibroblast Growth Factor- AFGF z Platelets Derived Growth Factor- PDGF z Vascular Endothelial Growth Factor- VEGF
Background image of page 14
VEGF Stimulation of Angiogenesis VEGFR2 VEGF PLC γ 1 PI3 kinase Morphogenesis Cell Proliferation
Background image of page 15

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Methods of Delivery z Daily Injections z VEGF in the crosslinked collagen matrix z VEGF in suspension in pores of matrix z Controlled release microparticles
Background image of page 16
Controlled Release particles Controlled Release particles z Optimize rate of vascularization by altering: Number/VEGF Concentration of Microcapsules Location of Microcapsules Size of Microcapsules
Background image of page 17

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Microcapsule Diffusion Model Microcapsule Diffusion Model z A model of the VEGF’s motion through the implant could be created and used to create a more-effective product z If a model with predictive capabilities was created, then the ideal initial concentration and placement of the microbeads could be determined
Background image of page 18
Z=y(t) Z=-L at y(0) Microcapsule Diffusion Model z No flux across top layer: ( δ c/ δ z = 0 @ z=L) z
Background image of page 19

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 20
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 72

Skin Tissue Replacement-Powerpoint presentation - REPLIDERM...

This preview shows document pages 1 - 20. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online